Lv11
80 积分 2024-06-03 加入
恩沃利单抗联合仑伐替尼和GEMOX方案一线治疗晚期不可切除肝内胆管癌的临床研究
4天前
已完结
Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience
1个月前
已完结
Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma
1个月前
已完结
不可切除肝内胆管癌的介入治疗研究进展
1个月前
已完结
Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma
3个月前
已完结
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis
3个月前
已完结
Revisiting resectability of biliary tract cancers, in the triplet drug therapy era with immune checkpoint inhibitors
3个月前
已完结
皖公网安备34019202002308